

A CAREFUL LOOK BACK,
AS YOU BEGIN TO LOOK AHEAD



Present

YEAR IN REVIEW
**BREAST
CANCER**

The year that was...2015



Dear Colleagues,

Women`s Cancer Initiative - Tata Memorial Hospital and Nag Foundation are delighted to invite you for the 1st Year in Review : Breast Cancer Conference to be held on 16th-17th Jan 2016 at R.D.Choksi Auditorium, Tata Memorial Hospital, Parel, Mumbai

Our idea is to recapitulate the best of breast cancer science presented at major conferences every year as a Year in Review format. The theme of this years' meeting is "Breast Cancer: The year that was.....2015". This meeting is proposed to be held every year on the 3rd weekend of January over 2 days. It aims to capture the best original scientific abstracts and deliberations covered in conferences that took place in the preceding year.

In this major conference we aim to cover surgical, radiation and medical oncology, pathology, biomarkers and imaging related abstracts making this meeting truly multidisciplinary.

The most important abstracts with the highest impact chosen by the scientific committee will be presented giving the participant a feel of the entire landscape of breast cancer research of the preceding year. There will also be a rapid review presentation on additional abstracts. The selection of abstracts will be based on originality, innovation and their potential impact on changing clinical practice.

We do hope you can join us and be a part of this comprehensive meeting.

Wishing you a very happy and prosperous new year 2016.

Regards

Conference Chairpersons

Dr. Sudeep Gupta
Dr. Shona Nag

**International
Faculty**

Dr. Hope Rugo, USA
Dr. Shaheenah Dawood, Dubai

**Scientific
Committee**

Dr. Amit Agarwal
Dr. Amit Verma
Dr. Anusheel Munshi
Dr. Bhawna Sirohi
Dr. Chirag Desai
Dr. Govind Babu
Dr. G S Bhattacharyya
Dr. Hemant Malhotra
Dr. Hope Rugo
Dr. Nishitha Shetty
Dr. Nita Nair
Dr. Shaheenah Dawood
Dr. Shalaka Joshi
Dr. Sanjoy Chatterjee
Dr. Senthil Rajappa
Dr. Randeep Singh
Dr. T Raja
Dr. Vineet Gupta

**2015 Conferences
Reviewed**

ASCO Breast Symposium

**St.Gallen`s Early Breast Cancer
Consensus Conference**

IMPAKT Annual Meeting

AACR Annual Meeting

ASCO Annual Meeting

ASTRO Annual Meeting

ESTRO Annual Meeting

ESMO - ECC Annual Meeting

**Consensus Conference of
Advanced Breast Cancer 3**

**San Antonio Breast Cancer
Symposium**

Highlights of the Meeting



01

Comprehensive
update on
breast cancer

02

11 international
conferences
reviewed

03

Kyenote talk on
immunotherapy
in breast cancer

04

More than 100
abstracts to
be discussed

05

Exclusive 60
mins panel
discussions



About International Faculty



Dr. Hope Rugo, USA

Clinical Professor, Department of Medicine (Hematology/Oncology);
and Director, Breast Oncology Clinical Trials Program, UCSF
San Francisco, CA

Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.

Dr. Rugo is the Director of the Breast Oncology Clinical Trials Program, and is the principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late stage breast cancer. In addition, Dr. Rugo is working on studies to evaluate cognitive function in women receiving chemotherapy for breast cancer, as well as novel ways to reduce toxicity from therapy. Dr. Rugo has established collaborations with a number of other large academic medical centers for the purpose of expanding the novel therapies that are available for our patients, including herbal agents that appear to have an antitumor effect in the laboratory. She is an active member of the national cooperative group, CALGB, and is a founding member of the Breast Cancer Research Consortium, as well as serving as an investigator in the UCSF Breast SPORE (the Bay Area Specialized Program of Research Excellence in Breast Cancer). Dr. Rugo teaches medical students and physicians, and regularly lectures locally, nationally and internationally on subjects relating to the treatment of breast cancer. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families and friends from throughout the bay area.

Dr. Rugo graduated from the University of Pennsylvania School of Medicine in 1983. She completed a residency in internal medicine and primary care followed by a fellowship in hematology and oncology at the University of California San Francisco. She was a post-doctoral fellow in immunology participating in laboratory research at Stanford University from 1988-1990. In 1990, Dr. Rugo joined the faculty at UCSF in the Division of Hematology and Oncology. Dr. Rugo has been recognized for her excellence in both patient care and in teaching of both medical students and training physicians. She has received several awards including the Bank of America Gianini Foundation Award and a UCSF Clinical Cancer Center Investigator Research Program intramural award. In 2006, she was honored for her work in Breast Cancer Research by the Friends of the Breast Care Center.

National Faculty



Adwaita Gore, *Mumbai*
Amit Verma, *Delhi*
Amol Dongre, *Nagpur*
Anand Pathak, *Nagpur*
Anil Heroor, *Mumbai*
Anita Ramesh, *Chennai*
Anjana Sainani, *Mumbai*
Anusheel Munshi, *Delhi*
Arvind Kumar, *Patna*
Asha Kapadia, *Mumbai*
Ashish Bakshi, *Mumbai*
Ashish Singh, *Chennai*
Ashwini Budrukhar, *Mumbai*
Atul Sharma, *Delhi*
Avinash Deo, *Mumbai*
B K Smruti, *Mumbai*
Bhavesht Parikh, *Ahmedabad*
Bhavna Parikh, *Mumbai*
Boman Dhabar, *Mumbai*
C B Koppiker, *Pune*
Chirag Desai, *Ahmedabad*
D C Doval, *Delhi*
G S Bhattacharya, *Kolkata*
G.S.Chowdhary, *Mumbai*
Ganapathi Ramanan, *Chennai*
Gaurav Gupta, *Lucknow*
Gautam Goyal, *Chandigarh*
Govind Babu, *Bangalore*
Hemant Malhotra, *Jaipur*
Indumati Ambulkar, *Mumbai*
Jyoti Bajpai, *Mumbai*
Kaustav Talapatra, *Mumbai*
Krishna Prasad, *Mangalore*
Lalit Mohan Sharma, *Jaipur*
Linu Jacob, *Bangalore*
Mandar Nadkarni, *Mumbai*
Madhuchanda Kar, *Kolkata*
Mani Samson, *Chennai*
Manish Chandra, *Mumbai*
Manish Singhal, *Delhi*
Manisha Singh, *Patna*
Meenakshi Thakur, *Mumbai*

N K Warriar, *Calicut*
Naresh Somani, *Jaipur*
Nikhil Ghadyalpatil, *Hyderabad*
Nilesh Lokeshwar, *Mumbai*
Nishitha Shetty, *Mangalore*
Nita Nair, *Mumbai*
Nitesh Rohatgi, *Delhi*
P.K.Julka, *Delhi*
P.Raghuram, *Hyderabad*
Pranjali Gadgil, *Pune*
Purvish Parikh, *Mumbai*
Rajiv Sarin, *Mumbai*
Raju Chacko, *Vellore*
Ramesh Nimmagadda, *Chennai*
Ramesh Sarin, *Delhi*
Randeep Singh, *Delhi*
Ranga Roa, *Delhi*
Rejiv Rejendranath, *Chennai*
Rucha Kaushik, *Mumbai*
S Hukku, *Delhi*
S.D.Banavali, *Mumbai*
S.H.Advani, *Mumbai*
Sachin Hingmire, *Pune*
Sanjay Sharma, *Mumbai*
Sanjoy Chatterjee, *Kolkata*
Santam Chakraborty, *Mumbai*
Shailesh Bondarde, *Nasik*
Shalaka Joshi, *Mumbai*
Shona Nag, *Pune*
Shyam Aggarwal, *Delhi*
Sidharth Sahni, *Delhi*
Somashekar SP, *Bangalore*
Subhasini John, *Vellore*
Sudeep Gupta, *Mumbai*
Sushil Mandhaniya, *Nagpur*
SVSS Prasad, *Hyderabad*
T P Sahoo, *Bhopal*
T Raja, *Chennai*
Tabassum Wadasadawala, *Mumbai*
Tanuja Shet, *Mumbai*
Tanveer Maksud, *Suraj*
Tejinder Singh, *Mumbai*
Vineet Gupta, *Bangalore*
Vinod Raina, *Delhi*

Scientific Program

Day 1 - Saturday, 16th January 2016

08:30-09:00

Registration

09:00-11:30 Session 1 : Loco-Regional Breast Cancer



chairpersons : P.K.Julka , Raghuram Pillarseti

09:00-09:10



Higher 10-year overall survival after breast conserving therapy compared to mastectomy in early stage breast cancer: a population-based study with 37,207 patients

Author: Van Maaren MC

Conference: SABCS



Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy

Author: R.G. Margolese

Conference: ASCO



Reviewer: Sidharth Sahni

09:10-09:25



Omitting are excision for a focally positive surgical margin after primary breast conserving surgery is safe.(Netherlands)

Author: E. Vos

Conference: ESMO



Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial

Author: J. Vaidya

Conference: ESTRO



Comparison of Complication and Reconstruction Failure in Radiated Patients With Breast Autologous Tissue and Tissue Expander/Implant Based Reconstruction

Author: Neil Woody

Conference: ASTRO




Reviewer: C.B.Koppiker

Scientific Program



Day 1 - Saturday, 16th January 2016

09:25-09:35

-  Whole exome sequencing of circulating and disseminated tumour cells in patients with metastatic breast cancer

Author: D. Peeters

Conference: IMPAKT

-  Development and validation of multiplex digital PCR assays on circulating tumor DNA in advanced breast cancer: Implementation for clinical routine use


Author: I. Garcia-Murillas

Conference: IMPAKT



Reviewer: Purvish Parikh

09:35-09:55

-  Late side-effects of breast cancer radiotherapy: Second cancer incidence and non breast-cancer mortality among 40,000 women in 75 trials


Author: Taylor C

Conference: SABCS

-  Long-term Toxicity and Outcomes of Hypofractionated Radiation Therapy With an Incorporated Boost for Early-Stage Breast Cancer

Author: Lora Wang

Conference: ASTRO

-  Long-term Risk of Breast Cancer Mortality After Local Failure in Women Treated With Breast Conserving Therapy

Author: Colin Murphy

Conference: ASTRO

-  Accelerated Partial Breast Irradiation Using Sole Interstitial Multicatheter Brachytherapy vs Whole Breast Irradiation for Early Breast Cancer: 5-year Results of a Randomized Phase III Trial - Part 1: Local Control and Survival Results


Author: V. Strnad

Conference: ASTRO




Reviewer: Anusheel Munshi

09:55-10:10

-  Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar trials


Author: D. Krug

Conference: ASCO

-  Regional nodal irradiation in early-stage breast cancer

Author: Whelan TJ,

Reference: N Engl J Med 373:307-316, 2015

 **Internal mammary and medial supraclavicular irradiation in breast cancer**
Author: Poortmans PM *Reference: N Engl J Med 373:317-327, 2015*


 **Dexamethasone vs Placebo in the Prophylaxis of Radiation-induced Pain Flare Following Palliative Radiation Therapy for Bone Metastases: A Double-blind Randomized, Controlled, Superiority Trial**
Author: E Chow *Conference: ASTRO*

 **Reviewer: Ashwini Budrukkar**


10:10-10:30

 **Tea/Coffee Break**


10:30-11:30


 **Panel Discussion on loco regional breast cancer**
Moderator: Sanjoy Chatterjee
Panelist: Pranjali Gadgil, Subhasini John, Sanjay Sharma, Mandar Nadkarni, Anil Heroor, Kaustav Talpatra, Somashekar SP, Tabassum W, Rucha Kaushik, Ramesh Sarin, Manish Chandra


11:30-15:00 Session 2 : ER Positive Breast Cancer and others

 **Chairperson : Ramesh Nimmagadda, N K Warriar**

11:30-11:45

 **ALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer**
Author: Andrew Louis Himelstein *Conference: ASCO*

 **The Impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial**
Author: Gnani M *Conference: SABCS*

 **Low hormone receptor (HR) status and the benefit of hormonal therapy (HT) in patients with early breast cancer (EBC)**
Author: C. Guarducci *Conference: IMPAKT*


 **Reviewer: Rajiv Sarin**

Scientific Program




Day 1 - Saturday, 16th January 2016

11:45-11:55

-  A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04)

Author: Lee S-J

Conference: SABCS

-  Consensus on breast cancer cell lines classification for an effective and efficient clinical decision making


Author: H. Milioli

Conference: IMPAKT




Reviewer: Randeep Singh

11:55-12:10

-  A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative (ER+HER2-) breast cancer (BC)


Author: Ma CX

Conference: SABCS

-  Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD L1-positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028

Author: Rugo HS

Conference: SABCS

-  High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERG1, a randomized Phase II study testing pictilisib (GDC-0941) in combination with fulvestrant (F) in pts that failed a prior aromatase-inhibitor (AI)


Author: Gendreau S

Conference: SABCS




Reviewer: Govind Babu

12:10-12:25

-  EndoPredict (EPclin) score for estimating residual distant recurrence (DR) risk in ER+/HER2- breast cancer (br ca) patients treated with 5 years adjuvant endocrine therapy alone: Validation and comparison with the oncotype DX recurrence score (RS)

Author: Dowsett M

Conference: SABCS

 "BEST ABSTRACT: Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry"


Author: J. Sparano


Conference: ESMO

 Reviewer: Mandar Nadkarni


12:25-13:00 Debate

12:25-12:40

 I will use oncotype DX in Er+ve Breast Cancer Patients

 Reviewer: Nitesh Rohatgi

12:40-12:55

 I will not use oncotype DX in Er+ve Breast Cancer Patients

 Reviewer: Shaheenah Dawood

12:55-13:00 Conclusion of debate

13:00-14:00

 Lunch Break

14:00-15:00

 Panel Discussion ER Positive Breast Cancer

Moderator : T Raja

Panelist: Govind Babu, Lalit Mohan Sharma, Jyoti Bajpai


Amol Dongre, Ranga Rao, Manisha Singh

Tejinder Singh, Bhavna Parikh, SVSS Prasad, Nikhil Ghadyal Patil

15:00-17:30 Session 3 : HER2 Positive Breast Cancer

 Chairpersons : D C Doval, Asha Kapadia

15:00-15:20


 Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET)

Author: A. Chan

Conference: ASCO


Scientific Program

Day 1 - Saturday, 16th January 2016

 Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3 year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET)


Author: A. Chan

Conference: SABCS

 NSABP FB-7: A phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer

Author: Jacobs S

Conference: SABCS


 A phase III randomized study of paclitaxel and trastuzumab versus paclitaxel alone for early stage, ER and PR receptor negative and HER2-positive breast cancer as adjuvant treatment

Author: M. Singhal

Conference: IMPAKT


 **Reviewer: Manish Singhal**

15:20-15:35

 Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab + endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer


Author: Harbeck N

Conference: SABCS

 Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2 positive hormone-receptor-positive early breast cancer: WSGADAPTher2/HR phase II trial

Author: Harbeck N

Conference: ASCO

 Phase III, randomised study of trastuzumab emtansine (T-DM1), pertuzumab (P) vs trastuzumab taxane (HT) for first line treatment of HER2 positive MBC: primary results from MARIANNE study

Author: P.A. Ellis


Conference: ASCO

 **Reviewer: TP Sahoo**

15:35-15:55


 Tea/Coffee Break

15:55-16:05

-  "ORAL Neoadjuvant chemotherapy with trastuzumab or lapatinib: Survival analysis of the HER2 positive cohort of the GeparQuinto study (GBG 44)"

Author: M. Untch

Conference: ESMO


-  Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P)

Author: L. Gianni

Conference: ASCO


 **Reviewer: Sachin Hingmire**

16:05-16:15

-  The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat?

Author: Van Ramshorst MS

Conference: SABCS


-  Prophylactic beta blockade preserves left ventricular ejection fraction in HER2 overexpressing breast cancer patients receiving trastuzumab: Primary results of the MANTICORE randomized controlled trial

Author: Pituskin E

Conference: SABCS


 **Reviewer: Adwaita Gore**

16:15-16:25

-  Functional subtyping with Blueprint 80-gene profile to identify distinct triple-positive subtypes with and without trastuzumab/chemosensitivity. 2015 Breast Cancer Symposium

Author: Peter D. Beitsch

Conference: ASCO breast Symposium

-  Discordance between HER2-phenotype on circulating tumor cells and primary tumor in women with advanced breast cancer

Author: A. Schramm

Conference: ASCO

 **Reviewer: Nilesh Lokeshwar**

Scientific Program



Day 2 - Sunday, 17th January 2016

16:30-17:30



Panel Discussion on HER Positive Breast Cancer

Moderator: B K Smruti, Hemant Malhotra

Panelist: Avinash Deo, Vinod Raina, Anita Ramesh

Shaheenah Dawood, Anand Pathak, Indumati Ambulkar

Arvind Kumar, Gautam Goyal, Anjana Sainani, Tanveer Maksud

19:00 onwards




Dinner at Hotel ITC Grand Central, Parel

Scientific Program




Day 2 - Sunday, 17th January 2016

09:00-11:00 Session 4 : Genomics/Translational Science


 Chairpersons : Naresh Somani, Madhuchanda Kar

09:00-09:15

 Interim analysis of multiplex gene panel testing for inherited susceptibility to breast cancer


Author: Idos G

Conference: SABCS

 Exome based germline mutation detection in a panel of 372 cancer associated genes in BRCA 1/2 negative familial breast cancer patients

Author: Shahi R

Conference: SABCS


 Results of the OPTIMA(Optimal Personalized Treatment of early breast cancer using Multiparameter Analysis) prelim study

Author: R. Stein

Conference: ESMO


 **Reviewer: Shalaka Joshi**

09:15-09:25

 White adipose tissue inflammation and breast cancer progression

Author: N. M. Iyengar

Conference: ASCO


 A Large Prospectively Designed Study of the DCIS Score: Recurrence Risk After Local Excision For Ductal Carcinoma In Situ Patients With and Without Irradiation

Author: Eileen Rakovitch

Conference: ASTRO


 **Reviewer: Nita Nair**

09:25-09:35

 Integrative Radiotranscriptomic Analysis of Breast Carcinoma Identifies Androgen Receptor as a Target for Therapeutic Sensitization

Author: B. Yard

Conference: ASTRO


 The PARP inhibitor olaparib is effective as radiosensitizer at 10-fold lower doses than as single agent

Author: R. De Haan

Conference: ESTRO


 **Reviewer: Santam Chakraborty**

09:35-09:45

 The driver landscape of breast cancer metastasis and relapse. 2015 European Cancer Congress

Author: Yates L

Conference: ESMO


 Genomic sequencing in metastatic breast cancer patients to inform clinical practice at the University of North Carolina at Chapel Hill

Author: Grilley-Olsen J

Conference: SABCS

 **Reviewer: Amit Verma**


09:45-10:30

 **Panel Discussion on genomics and translational science**

Moderator: Hope Rugo

Panelist: Tanju Shet, Amit Verma, Raju Chacko
Atul Sharma, G S Bhattacharya, Linu Jacob
Chirag Desai, Nishita Shetty, M. Samson
Ramesh Nimmagadda

10:30-11:00

 Chairpersons: S.D.Banavali, G.S. Chowdhury


 Immunotherapy in breast cancer

 Speaker: Hope Rugo

11:00-11:20

 Tea/Coffee Break

11:20-13:00 Session 5 : TNBC

 Chairpersons: S H Advani, S Hukku

11:20-11:30

Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)


Author: Von Minckwitz G

Conference: SABCS

Scientific Program



Day 2 - Sunday, 17th January 2016

-  Event-free and overall survival following neoadjuvant weekly paclitaxel and dose dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance)


Author: Sikov WM

Conference: SABCS




Reviewer: Vineet Gupta

11:30-11:45

-  Profiles of genome complexity identify HORMAD1 as a driver of homologous recombination deficiency and platinum therapy response in triple-negative breast cancer "


Author: A. Grigoriadis

Conference: IMPAKT

-  TITAN: Phase III study of doxorubicin/cyclophosphamide (AC) followed by ixabepilone (Ixa) or paclitaxel (Pac) in early-stage, triple-negative breast cancer (TNBC)

Author: D. A. Yardley

Conference: ASCO

-  Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor negative early breast cancer (BC)


Author: M. Colleoni

Conference: ASCO




Reviewer: Rejiv Rajendranath

11:45-12:00

-  Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR triple-negative breast cancer (TNBC)


Author: T. A. Traina

Conference: ASCO

-  Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple negative breast cancer (aTNBC)

Author: J. Cortés

Conference: ESMO

-  Phase III trial of etirinotecan pegol (EP) versus treatment of physician's choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study

Author: E. A. Perez

Conference: ASCO




Reviewer: Krishna Prasad

12:00-12:15

-  A phase Ib study of pembrolizumab (MK-3475) in patients (pts) with metastatic triple negative breast cancer (mTNBC).


Author: L. Buisseret

Conference: IMPAKT

-  Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC

Author: A. Bardia

Conference: SABCS

-  Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple negative breast cancer (TNBC). Abstract 2859. Presented at: 2015 American Association for Cancer Research (AACR) Meeting; April 18-22, 2015; Philadelphia, PA

Author: Emens LA

Conference: AACR 2015



Reviewer: Shyam Aggarwal

12:15-13:00



Panel Discussion on TNBC

Moderator: Ashish Bakshi

*Panelist: Shyam Aggarwal, Shailesh Bondarde, Ganapathy Ramanan
 Ashish Singh, Gaurav Gupta, Bhavesh Parikh,
 Boman Dhabhar, Sushil Mandhaniya*

13:00-13:40 Session 6 : Rapid Reviews




Chairpersons : Somashekhar S P, Meenakshi Thakur

13:00-13:40




Reviewers: Shona Nag, Sudeep Gupta

-  1. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial

Author: Dirix LY

Conference: SABCS

-  2. Importance of margin width and re-excision in breast conserving treatment of early breast cancer; a Danish Breast Cancer Cooperative Group study of 11,900 women


Author: Bodilsen A


Conference: SABCS


Scientific Program





Day 2 - Sunday, 17th January 2016


-  3. cfDNA analysis from BOLERO-2 plasma samples identifies a high rate of ESR1 mutations: Exploratory analysis for prognostic and predictive correlation of mutations reveals different efficacy outcomes of endocrine therapy-based regimens
Author: Chandarlapaty S *Conference: SABCS*


-  4. HER2 status as predictive marker for AI vs Tam benefit: a TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
Author: Bartlett JMS *Conference: SABCS*


-  5. Ten year follow-up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC[®]T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC[®]TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer patients
Author: Slamon DJ *Conference: SABCS*











-  6. Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study
Author: Wildiers H *Conference: SABCS*

-  7. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2- advanced breast cancer (BC): First results from the randomized, Phase III BELLE-2 trial
Author: J. Baselga *Conference: SABCS*

-  8. Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and safety results of the femara versus anastrozole clinical evaluation (Face) trial
Author: O'Shaughnessy J *Conference: SABCS*

-  9. NEO-EXCEL phase III neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER positive postmenopausal early breast cancer
Author: Francis A *Conference: SABCS*











-  10. Final results of a first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-Endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781)
Author: Goetz MP *Conference: SABCS*











-  11. HERA trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer - Final analysis
 Author: Jackisch C Conference: SABCS
-  12. Effects of perioperative lapatinib in early HER2+ breast cancer - The UK EPHOS-B trial (CRUK/08/002)
 Author: N. Bundred Conference: SABCS
-  13. High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized Phase II study testing pictilisib (GDC-0941) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor (AI)
 Author: S. Gendreau Conference: SABCS
-  14. A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predicts degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B31 for HER2+ breast cancer
 Author: Seong-Rim Kim Conference: AACR
-  15. p53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy - A translational subproject of the GeparSixto trial
 Author: S. Darb-Esfahani Conference: IMPAKT
-  16. Somatic BRCA1 mutations determine different responses to platinum-based chemotherapy
 Author: E. Ignatova Conference: IMPAKT
-  17. Histology and molecular characteristics of pregnancy associated breast cancer
 Author: Z. Tomasevic Conference: IMPAKT
-  18. Evaluation of PDL1 expression in breast cancer by immunohistochemistry
 Author: C. Solinas Conference: IMPAKT
-  19. Targeting unique metabolic vulnerabilities in dormant ER+ tumor cells
 Author: E. Knudsen Conference: IMPAKT
-  20. Smart delivery of lapatinib to reduce its cardiotoxicity: A 99mTc labeled biodistribution study
 Author: A. Khanna Conference: IMPAKT

Scientific Program












Day 2 - Sunday, 17th January 2016

-  21. Clinical patterns of metastatic spread from formalin-fixed, paraffin-embedded (FFPE) expression profiles: A case-control study of 1,357 breast cancer patients
Author: K. Lawler *Conference: IMPAKT*
-  22. Evolution from primary breast cancer to relapse and metastasis
Author: L. Yates *Conference: ESMO*
-  23. The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast
Author: Y. Sagara *Conference: ASCO*
-  24. Recurrence rates for ductal carcinoma in situ: Analysis of 2,996 patients treated with breast-conserving surgery over 30 years
Author: Kimberly J. Van Zee *Conference: ASCO Breast Symposium*
-  25. Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial
Author: M. Gnant *Conference: ASCO*
-  26. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307
Author: J. Gralow *Conference: ASCO*
-  27. Effect of regular exercise on survival in women with early stage luminal-a breast cancer
Author: O. Yazici *Conference: ESMO*
-  28. "Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial"
Author: Arlene Chan *Conference: ASCO Breast Symposium*
-  29. Short and Long-term Toxicity and Cosmesis After Interstitial Multicatheter Brachytherapy for Accelerated-Partial Breast Irradiation: A Multi-institutional Study
Author: Robert Kuske *Conference: ASTRO*
-  30. Impact of Ipsilateral Blood Pressure Measurements, Blood Draws, Infusions, and Air Travel on the Risk of Lymphedema for Patients Treated for Breast Cancer: A Prospective Study
Author: Alphonse Taghian *Conference: ASTRO*

-  31. Impact of Sequencing Radiation Therapy and Chemotherapy on Long-term Local Toxicity for Early Breast Cancer: Results of a Randomized Study at 15 Year Follow up.
 Author: Paola Pinnaro Conference: ASTRO
-  32. Physician-driven variation in non-recommended imaging for women with early stage breast cancer
 Author: A. N. Lipitz Snyderman Conference: ASCO
-  33. Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer
 Author: D. L. Wickerham Conference: ASCO
-  34. Breast MRI screening of women at average risk of breast cancer: An observational cohort study
 Author: Christiane K. Kuhl Conference: ASCO Breast Symposium
-  35. Agreement in risk assessment among breast cancer specialists: A survey within the MINDACT cohort
 Author: C. Drukker Conference: IMPAKT
-  36. Outcome analysis of patients with breast cancer and positive sentinel node
 Author: A. Syed Conference: IMPAKT
-  37. Male breast cancer receptor sub-types: Demographics, tumor characteristics and short term survival outcomes
 Author: S. Yadav Conference: IMPAKT
-  38. Examination of the sentinel lymph node identification in breast cancer combining contrast enhanced ultrasonography and the blue dye method without radioisotope
 Author: K. Futsuhara Conference: IMPAKT
-  39. Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto
 Author: G. Von Minckwitz Conference: ASCO
-  40. Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2 positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance)
 Author: M. Golshan Conference: ASCO



Day 2 - Sunday, 17th January 2016

-  41. NRG Oncology/RTOG 1014: 1 Year Toxicity Report From a Phase II Study of Repeat Breast Preserving Surgery and 3-D Conformal Partial-Breast Reirradiation (PBrl) for In-Breast Recurrence
Author: Douglas Arthur *Conference: ASTRO*
-  42. Concordance of local and central HER2 status in 1597 patients participating in German neoadjuvant breast cancer studies.
Author: B. Pfitzner *Conference: IMPAKT*
-  43. PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptorpositive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy
Author: N. C. Turner *Conference: ASCO*
-  44. Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance)
Author: M. N. Dickler *Conference: ASCO*
-  45. Final results for overall survival(OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV- PAC) vs BEV capecitabine (CAP) for HER2 negative locally recurrent/metastatic breast cancer (LR/mBC)
Author: T. Brodowicz *Conference: ESMO*
-  46. Association between HER2 phenotype on circulating tumor cells and primary tumor characteristics in women with metastatic breast cancer.
Author: W. Janni *Conference: ESMO*
-  47. Targeting HER2 in patients with HER2-negative metastatic breast cancer with elevated serum levels of the HER2 extracellular domain and/or HER2-positive circulating tumor cells in the clinical routine
Author: C. Kurbacher *Conference: IMPAKT*
-  48. Radiotherapy plus trastuzumab in the treatment of Her2-positive locally advanced breast cancer
Author: A. Belokhvostova *Conference: IMPAKT*
-  49. "High risk premenopausal luminal A breast cancer patients derive no benefit from adjuvant chemotherapy: results from DBCG77B randomized trial"
Author: Nielsen TO *Conference: SABCS*

Scientific Program



Day 2 - Sunday, 17th January 2016

13:40-13:45



Vote of thanks

13:45 onwards



Lunch and departures



Registration Form

(Please fill the form in capital letters)

Participants Details:

Name : _____ Surname : _____

Institution : _____

Department : _____

Specialization : _____ Main Field : _____

Address Of Correspondence : _____

City : _____ Zip Code : _____ Country : _____

Tel : _____ Fax : _____

Mobile : _____ Email ID : _____

Payment Details : Amount _____ DD / Cheque No : _____

Bank Name : _____

Conference Registration Fee

Registration Upto 11 th Jan 2016	Delegates	Rs. 1500/-
	Students	Rs. 500/-

Kindly make the Demand Drafts or Cheque in favor of "NAG Foundation" & Courier it along with the registration form to the below address of conference secretariat. Students are requested to submit necessary proof from HOD
For more information on registration please visit www.wci.co.in/conference/yir/registration or write to yir.breastcancer@gmail.com

Conference Secretariat :



Nimesh Bafna

RIVER ROUTE Creative Group Pvt. Ltd.

Krishna Bldg No.2, Flat No.8, Gokhale Society Lane, Parel, Mumbai - 400012

Mobile: +91 9821079650 Tel: +91 22 24146482/83, Email: yir.breastcancer@gmail.com

This meeting is supported by unrestricted educational grant from:

Emcure
SUCCESS THROUGH INNOVATION